Tianjin, February [20], 2023 - CanSino Biologics Inc. ("CanSinoBIO" or "the Company") (SSE: 688185, HKEX: 06185) announced that Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, recently published[1] the phase IIb trial results of CanSinoBIO's mRNA COVID-19 vaccine ("CS-2034"). The results of the study indicated that heterologous boosting with CS-2034 induced higher levels of immune responses and protection against the original SARS-CoV-2 and Omicron infections than homologous boosting in adults aged 18 and above, who have received three prior doses of inactivated COVID-19 vaccine.

The study was conducted during the recent outbreak in China driven by Omicron BA.5.2 and BF.7 subvariants. Real world data showed that CS-2034 demonstrates a favorable safety profile and proven efficacy and provides broader protection against COVID-19 infections than homologous inactivated booster by inducing high-titer neutralizing antibodies against multiple SARS-CoV-2 strains. The geometric mean titer ("GMT") of neutralizing antibodies against BA.5 peaked at Day 7 following the booster vaccination and represented a mean 29 times that induced by a homologous inactivated booster. The neutralizing antibody levels against BA.5 were 34.7 and 14.4 times that observed in the inactivated booster group at Day 14 and Day 28, respectively.

In addition, 7 days after inoculation, CS-2034 induced strong cellular immunity, and the frequency of IFN-γ, IL-2, IL-5 and IL-13 positive T cells was significantly higher than those boosted with homologous inactivated vaccines.

CanSinoBIO's mRNA technology platform is equipped with its proprietary sequence optimization software that can effectively identify key gene loci and improve antigen expression. As one of CanSinoBIO's five core technology platforms, the Company's mRNA platform has significant advantages in R&D as it can more easily adapt to new variants to shorten the production cycle, contributing to scalability and faster commercialization of vaccine production. mRNA vaccines have significant potential in a wide range of applications in addition to COVID-19 vaccine, such as the flu vaccine, COVID+flu vaccine, and Respiratory Syncytial Virus ("RSV") vaccine.

Established in July 2021 in Shanghai, CanSinoBIO's mRNA facility has entered the trial production stage, with a designed production capacity of 100 million doses per year. The Company is currently preparing for the phase III clinical trial study for CS-2034.

[1]Source: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4356787

Attachments

Disclaimer

Cansino Biologics Inc. published this content on 20 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 February 2023 02:29:04 UTC.